After FDA Review, GSK Could Earn Reprieve On Avandia
The U.S. Food and Drug Administration on Monday potentially moved closer to loosening restrictions on GlaxoSmithKline PLC's former blockbuster diabetes drug Avandia, after agency researchers backed a study downplaying the purported...To view the full article, register now.
Already a subscriber? Click here to view full article